Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 20 de 3070 siguiente >>
Presentar resultados
Seleccionar todas
2.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
3.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019:25 de marzo. [Ref.ID 103073]
4.Enlace a cita original Cita con resumen
Anónimo. FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. FDA U.S. Food and Drug Administration 2019:22 de marzo. [Ref.ID 103071]
6.Enlace a cita original Cita con resumen
Beall RF, Hwang TJ, Kesselheim AS. Major events in the life course of new drugs, 2000–2016. N Engl J Med 2019;380:14 de marzo. [Ref.ID 103056]
7.Enlace a cita original Cita con resumen
Byrd JB, Chertow GM, Bhalla V. Hypertension hot potato — Anatomy of the angiotensin-receptor blocker recalls. N Engl J Med 2019;380:25 de abril. [Ref.ID 103055]
9. Cita con resumen
Anónimo. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). FDA U.S. Food and Drug Administration 2019:21 de febrero. [Ref.ID 103045]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Chambers HF. Omadacycline — The newest tetracycline. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103037]
12. Cita con resumen
13. Cita con resumen
Taylor P. Finch’s microbiota drug for C. diff gets FDA breakthrough status. PMLiVE 2019:11 de febrero. [Ref.ID 103019]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
16. Cita con resumen
Thielking M. FDA panel says overdose antidote should be prescribed with opioids. STAT Morning Rounds 2018:3. [Ref.ID 102906]
17. Cita con resumen
Healy D. The Goetzsche affair. Dr. David Healy (blog) 2018:5 de noviembre. [Ref.ID 102892]
18. Cita con resumen
Cooney E. Novartis unit teams up with medical marijuana producer, marking milestone for pharma. STAT Daily Recap 2018:18 de diciembre. [Ref.ID 102888]
19.Enlace a cita original Cita con resumen
Wallach JD, Eqilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ 2018;361:24 de mayo. [Ref.ID 102886]
Seleccionar todas
 
 1 a 20 de 3070 siguiente >>